EUVIMEDEUVIMED entdecken
Crossref

Multicyclic Peptides Targeting PD-L1 for Radiotheranostics: From Discovery to Clinical Proof-of-Concept

Xueting Cheng iD, Shuo Jiang, Xingtong Peng, Pan Yang, Siqi Zhang, Chaoying Xu, Xin Gao, Shihui Fan, Hongtan Liu, Jie Zhuang, Xueyao Chen, Naixin Liang und 8 weitere

Journal of the American Chemical Society · 2025

DOI: 10.1021/jacs.5c11292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2025. Verfasst von Xueting Cheng und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Chemistry and Chemical Engineering, The MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, State…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Radiopharmaceuticals, Peptides, Cyclic. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenRadiopharmaceuticalsPeptides, CyclicHumansAnimalsMicePositron-Emission TomographyProof of Concept StudyGallium RadioisotopesTheranostic NanomedicineNeoplasmsCell Line, Tumor

Substanzen

B7-H1 AntigenRadiopharmaceuticalsPeptides, CyclicCD274 protein, humanGallium RadioisotopesGallium-68

Autor:innen und Institutionen

  • Department of Chemistry, College of Chemistry and Chemical Engineering, The MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, State Key Laboratory of Physical Chemistry of Solid Surfaces, Xiamen Univer…
  • State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050, P.R. China.
  • Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Ch…
  • School of Pharmacy, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, P.R. China.
  • Chongqing Innovation Institute of China Pharmaceutical University, Chongqing 401135, P.R. China.
  • Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, P.R. China.

ORCID-Profile: Xueting Cheng, Zhaohui Zhu, Rui Wang, Kuan Hu, Chuanliu Wu

Förderung

  • Chinese Academy of Medical Sciences
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • Beijing Nova Program

Zitieren

APA

Cheng, X., Jiang, S., Peng, X., Yang, P., Zhang, S., Xu, C., Gao, X., Fan, S., Liu, H., Zhuang, J., Chen, X., Liang, N., Lin, B., Lu, Q., Chen, M., Xiao, Y., Zhu, Z., Wang, R., Hu, K., & Wu, C. (2025). Multicyclic Peptides Targeting PD-L1 for Radiotheranostics: From Discovery to Clinical Proof-of-Concept. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.5c11292

Vancouver

Cheng X, Jiang S, Peng X, Yang P, Zhang S, Xu C, et al. Multicyclic Peptides Targeting PD-L1 for Radiotheranostics: From Discovery to Clinical Proof-of-Concept. Journal of the American Chemical Society. 2025. doi:10.1021/jacs.5c11292

BibTeX
@article{Cheng2025,
  author = {Cheng, Xueting and Jiang, Shuo and Peng, Xingtong and Yang, Pan and Zhang, Siqi and Xu, Chaoying and Gao, Xin and Fan, Shihui and Liu, Hongtan and Zhuang, Jie and Chen, Xueyao and Liang, Naixin and Lin, Bingni and Lu, Qingshuang and Chen, Meirong and Xiao, Yibei and Zhu, Zhaohui and Wang, Rui and Hu, Kuan and Wu, Chuanliu},
  title = {Multicyclic Peptides Targeting PD-L1 for Radiotheranostics: From Discovery to Clinical Proof-of-Concept},
  journal = {Journal of the American Chemical Society},
  year = {2025},
  doi = {10.1021/jacs.5c11292}
}
Kostenlos starten →